In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)

Table 2 MICs/MBCs (mg/L) of magnolol (ML), honokiol (HL) and conventional antibacterial agents against MSSA and the ten MRSA strains^a

^aMSSA Methicillin-susceptible Staphylococcus aureus (ATCC25923), MRSA Methicillin-resistant Staphylococcus aureus
^bML Magnolol, HL Honokiol, AMK Amikacin, ETM Etilmicin, GEN Gentamicin, PIP Piperacillin, CIP Ciprofloxacin, LEV Levofloxacin, FOS Fosfomycin, NOR Norfloxacin, VAN Vancomycin
^c50 % = MIC₅₀/MBC_50, i.e. the minimal inhibitory and bactericidal concentrations required to inhibit and kill 50 % of the strains, respectively
^b90 % = MIC₉₀/MBC₉₀, i.e. the minimal inhibitory and bactericidal concentrations required to inhibit and kill 90 % of the strains, respectively
*p > 0.01

ISSN: 2662-7671